NCT06376084View on ClinicalTrials.gov

Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC

Active, not recruitingOBSERVATIONAL

Enrollment

533

Participants

Timeline

Start Date

July 23, 2024

Primary Completion Date

February 28, 2028

Study Completion Date

February 28, 2028

Conditions

Carcinoma, Non-Small-Cell LungLung NeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract DiseasesCarcinoma, BronchogenicBronchial Neoplasms

Trial Locations (1)

Unknown

Research Site, Shanghai